VRDN-001 demonstrated positive results at a low dose for the treatment of active thyroid eye disease in a phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.
The ongoing trial investigated two intravenous infusions of VRDN-001, an anti-insulin-like growth factor 1 receptor antibody, administered 3 weeks apart, at doses of 3 mg/kg, 10 mg/kg and 20 mg/kg. Each cohort included six participants randomly assigned to VRDN-001 and two participants randomly assigned to placebo. Efficacy was measured 6 weeks after the first dose. Positive results were previously reported